The CCP Virus vaccine will be offered to detainees at Guantanamo Bay, Cuba, as early as next week, the Pentagon has stated.
Prosecutor, Clayton G. Trivett Jr., who is working on the case against five prisoners accused of conspiring in the attacks on Sept. 11, 2001, informed defense lawyers on Thursday “that an official in the Pentagon has just signed a memo approving the delivery of the CCP virus vaccine to the detainee population in Guantánamo,” reported The New York Times.
Vaccination of the naval base residents of 6,000 that includes 1,500 U.S. troops, began early in January under the Trump administration, however at the time vaccination of prisoners was not clear.
Guantanamo at the moment houses 40 detainees, and the first of two required doses may be given “on a voluntary” basis as early as Monday, said Trivett. The prisoner’s consent is required for the shots, because the FDA has given only emergency-use authorization to the Moderna and Pfizer-BioNTech vaccines.
The number of cases of CCP Virus at the compound is not publicly known, and it has not been announced if Khalid Sheikh Mohammed, the self-proclaimed mastermind behind the 9/11 attacks, and his co-conspirators have agreed to take the shots.
Due to a lack of vaccine at the Camp Justice compound, war crime hearings have been delayed.
An arraignment for three prisoners accused of conspiring in deadly attacks in Indonesia in 2002 and 2003 has been scheduled for Feb. 22, and Breitbart News reported that if prisoners agree to the vaccine, the second dose could be administered the night before the arraignment.
The three detainees—Encep Nurjaman, who is known as Hambali; Mohammed Nazir Bin Lep; and Mohammed Farik Bin Amin—have been in U.S. custody since they were captured in Thailand in 2003.
Meanwhile, Johnson and Johnson released the results on its huge trials with a one-shot vaccine, and the results prove to be promising.
“Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. When those who received the vaccine did exhibit symptoms, they proved to be mild.
On Friday the pharmaceutical giant revealed the vaccine has shown to be more effective in the United States. “The level of protection against moderate and severe COVID-19 infection was 72 percent in the U.S., 66 percent in Latin America and 57 percent in South Africa, 28 days post-vaccination,” he said.